Healthcare / BiotechnologyTokyo
$28.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-1.3B · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-36.1%
↓Gross Margin
13.5%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.5%
FCF CAGR
—
FCF margin
-178.4%
FCF / Net income
1.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $810.3M · net income $-1.36B · FCF $-1.45B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $810.3M | $810.3M | $768.5M | $661.5M | $633.7M |
| Net Income | $-1.36B | $-1.36B | $-1.28B | $-1.44B | $-1.25B |
| EBITDA | $-1.26B | $-1.26B | $-1.16B | $-1.33B | $-1.14B |
| EPS | -5.15 | -5.15 | -5.04 | -6.65 | -6.33 |
| Gross Margin | 13.5% | 13.5% | 14.7% | 14.9% | 20.2% |
| Operating Margin | -178.4% | -178.4% | -180.2% | -215.5% | -210.4% |
| Net Margin | -168.1% | -168.1% | -166.2% | -217.4% | -197.9% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.00 | 0.00 | 0.00 |
| Current Ratio | 6.07 | 6.07 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.45B | $-1.45B | $-1.33B | $-1.35B | $-1.20B |
| Returns | |||||
| ROE | -36.1% | -36.1% | -24.6% | -28.5% | -22.8% |
| Valuation | |||||
| P/B | 1.96 | 1.96 | 2.15 | 2.01 | 2.98 |
| Growth & Yield | |||||
| Revenue Growth | 5.4% | 5.4% | 16.2% | 4.4% | — |
| EPS Growth | -2.2% | -2.2% | 24.2% | -5.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-5.04 → -5.15
Residual
-6.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.